In conclusion, we demonstrate the synergistic effect of the combination therapy with AKT (AZD5363) and mTOR (AZD2014 and BEZ235) inhibitors against bladder cancer cells with PI3KCA and mTOR mutations. Here, AKT1 is linked to urinary bladder cancer.